Abstract: Here is disclosed isolated or purified monoclonal antibodies, or an antigen-binding fragments thereof, which binds to human CD3, and which comprises: a CDRH1 amino acid sequence of SEQ ID NO: 150, a CDRH2 amino acid sequence of SEQ ID NO: 151, a CDRH3 amino acid sequence of SEQ ID NO: 152, a CDRL1 amino acid sequence of SEQ ID NO: 153, a CDRL2 amino acid sequence of SEQ ID NO: 154, and a CDRL3 amino acid sequence of SEQ ID NO: 155. Also provided are recombinant polypeptides comprising said monoclonal antibody, or an antigen-binding fragment thereof, such as multivalent antibodies, including bispecific T-cell engagers. Also described are chimeric antigen receptors (CARs) for CAR-T therapy comprising any one of the monoclonal antibodies, or antigen-binding fragments thereof. Nucleic acids encoding the aforementioned antibodies, fragments, and polypeptides are also disclosed, along with therapeutic applications in the treatment of and autoinflammatory disease or cancer.

Abstract: The present invention provides a vaccine comprising a peptide antigen, one terminal end being coupled to a carrier molecule, and the other terminal end of the peptide being linked to a non-immunogenic moiety such as a saccharide. The thus terminally-glycosylated conjugated-peptide provides better immune responses in mice, able to generate unique mouse antibodies specific to the core region of these linear peptide epitopes. Results from immunization of both BALB/c and A/J strain mice revealed that the terminal glycosylation led to better antibody response towards the central epitope.

Abstract: The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like. More specifically, the present invention provides novel group B meningococcal unsaturated N-acyl derivative polysaccharides, novel conjugates of the group B meningococcal unsaturated N-acyl derivative polysaccharides, pharmaceutical compositions comprising conjugate molecules of group B meningococcal unsaturated N-acyl derivative polysaccharide fragments covalently bound to proteins, and the use of these compositions as vaccines.

Abstract: The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like. More specifically, the present invention provides novel group B meningococcal unsaturated N-acyl derivative polysaccharides, novel conjugates of the group B meningococcal unsaturated N-acyl derivative polysaccharides, pharmaceutical compositions comprising conjugate molecules of group B meningococcal unsaturated N-acyl derivative polysaccharide fragments covalently bound to proteins, and the use of these compositions as vaccines.

Abstract: The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like, as well as antibodies to these conjugate vaccines. More specifically, the present invention provides novel group B meningococcal unsaturated N-acyl derivative polysaccharides, novel conjugates of the group B meningococcal unsaturated N-acyl derivative polysaccharides, pharmaceutical compositions comprising conjugate molecules of group B meningococcal unsaturated N-acyl derivative polysaccharide fragments covalently bound to proteins, and the use of these compositions as vaccines.

Abstract: The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like. More specifically, the present invention provides novel group B meningococcal unsaturated N-acyl derivative polysaccharides, novel conjugates of the group B meningococcal unsaturated N-acyl derivative polysaccharides, pharmaceutical compositions comprising conjugate molecules of group B meningococcal unsaturated N-acyl derivative polysaccharide fragments covalently bound to proteins, and the use of these compositions as vaccines.

Abstract: The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like. More specifically, the present invention provides novel group B meningococcal unsaturated N-acyl derivative polysaccharides, novel conjugates of the group B meningococcal unsaturated N-acyl derivative polysaccharides, pharmaceutical compositions comprising conjugate molecules of group B meningococcal unsaturated N-acyl derivative polysaccharide fragments covalently bound to proteins, and the use of these compositions as vaccines.